Status:
UNKNOWN
Contrast-enhanced Ultrasound and Pancreatic Lesions
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The characterization of pancreatic lesions is one of the fundamental steps in the management of pancreatic neoplastic diseases. In terms of a subjective assessment of vascular enhancement in the vario...
Detailed Description
Pancreatic cancer is currently one of the most prevalent malignant neoplasms, characterized by an increasing prevalence and a high mortality and lethality rate. It is the seventh most common malignant...
Eligibility Criteria
Inclusion
- Inclusion criteria are:
- written informed consent
- at least 18 years of age
- at least one pancreatic lesion visible in B-mode US and investigated trough CEUS
- Exclusion criteria:
- less than 18 years of age
- absence of informed consent
- knowm allergy to ultrasound contrast agent
- hearth failure
- pregnancy
- lactation
Exclusion
Key Trial Info
Start Date :
November 7 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05977777
Start Date
November 7 2022
End Date
June 1 2025
Last Update
August 4 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione Policlinico Gemelli IRCCS
Roma, Italy, 00168